Treatment of Oral Candidiasis in Immunocompetent Adults
For mild oral candidiasis in immunocompetent adults, start with topical clotrimazole troches (10 mg dissolved orally 5 times daily) or nystatin suspension (4-6 mL of 100,000 U/mL four times daily) for 7-14 days; for moderate to severe disease, use oral fluconazole 100-200 mg daily for 7-14 days. 1
Treatment Algorithm by Disease Severity
Mild Disease (First-Line Options)
- Clotrimazole troches: 10 mg dissolved slowly in mouth 5 times daily for 7-14 days 1
- Nystatin suspension: 100,000 U/mL, 4-6 mL swished and swallowed 4 times daily for 7-14 days 1
- Nystatin pastilles: 200,000 U each, 1-2 pastilles 4 times daily for 7-14 days 1
These topical options carry strong recommendations with high to moderate-quality evidence from the 2016 IDSA guidelines 1. The choice between agents depends on patient preference regarding taste, texture, and the required contact time with oral mucosa.
Moderate to Severe Disease
Oral fluconazole 100-200 mg daily for 7-14 days is the recommended systemic therapy 1. This represents a strong recommendation with high-quality evidence and has become the drug of choice due to superior efficacy, patient acceptance, and convenient once-daily dosing 2.
Management of Refractory Disease
If the patient fails to respond to fluconazole after 7-14 days (fluconazole-refractory disease):
Second-line options (strong recommendation, moderate-quality evidence) 1:
- Itraconazole solution: 200 mg once daily for up to 28 days
- Posaconazole suspension: 400 mg twice daily for 3 days, then 400 mg daily for up to 28 days
Alternative second-line agents 1:
- Voriconazole 200 mg twice daily
- Amphotericin B deoxycholate oral suspension 100 mg/mL four times daily
For severe refractory cases, intravenous therapy with echinocandins (caspofungin, micafungin, or anidulafungin) or IV amphotericin B deoxycholate may be necessary, though this carries only a weak recommendation 1.
Special Considerations
Denture-Related Candidiasis
Disinfection of the denture is mandatory in addition to antifungal therapy 1. Failure to address denture hygiene will result in treatment failure and recurrence, as the denture acts as a reservoir for Candida organisms.
Recurrent Infections
Chronic suppressive therapy is usually unnecessary in immunocompetent patients 1. However, if recurrent infections occur despite addressing predisposing factors, fluconazole 100 mg three times weekly can be used 1.
Critical pitfall: Before initiating suppressive therapy, investigate and correct underlying predisposing factors such as:
- Uncontrolled diabetes mellitus
- Inhaled corticosteroid use (without proper mouth rinsing)
- Antibiotic overuse
- Xerostomia
- Poor oral hygiene
- Ill-fitting dentures
Addressing Predisposing Factors
The 2016 IDSA guidelines emphasize that successful treatment requires identifying and managing local and systemic risk factors 1. This is particularly important in immunocompetent patients where candidiasis suggests an underlying predisposing condition 3, 4.
Important Clinical Caveats
Resistance patterns: Increasing reports of azole resistance, particularly with recurrent therapy, necessitate culture and susceptibility testing if initial treatment fails 5. Non-albicans Candida species (particularly C. glabrata and C. krusei) may exhibit intrinsic or acquired resistance to fluconazole 6.
Duration matters: The full 7-14 day course must be completed even if symptoms resolve earlier, as premature discontinuation increases recurrence risk.
Topical vs. systemic: While topical agents are preferred for mild disease to minimize systemic drug exposure and cost, they require good patient compliance with multiple daily doses and adequate contact time with oral mucosa 1, 5.